N
KYNB

Natixis’s Kyntra Bio KYNB Stock Holding History

Natixis’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,200
Closed -$26.6K – 1079
2023
Q4 		$26.6K Hold
1,200
– – ﹤0.01% 866
2023
Q3 		$25.9K Sell
1,200
-1,996
-62% -$78.4K ﹤0.01% 859
2023
Q2 		$216K Buy
+3,196
New +$1.32M ﹤0.01% 732
2022
Q1 		– Sell
-4,707
Closed -$1.66M – 1211
2021
Q4 		$1.66M Sell
4,707
-3,301
-41% -$1.03M 0.01% 819
2021
Q3 		$2.05M Buy
8,008
+440
+6% +$156K 0.01% 724
2021
Q2 		$5.04M Hold
7,568
– – 0.02% 379
2021
Q1 		$6.57M Hold
7,568
– – 0.02% 458
2020
Q4 		$7.02M Sell
7,568
-1,328
-15% -$1.4M 0.03% 457
2020
Q3 		$9.14M Buy
+8,896
New +$9.57M 0.07% 197
2018
Q4 		– Sell
-541
Closed -$821K – 729
2018
Q3 		$821K Buy
+541
New +$833K ﹤0.01% 586

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Natixis's KYNB Position: Q1 2024 in Review

Natixis sold out of Kyntra Bio (KYNB) in Q1 2024, closing a stake of 1,200 shares — an estimated $26.6K sold.

Natixis first reported a position in KYNB in Q3 2018 and held it in 10 quarters. The position peaked at $9.14M in Q3 2020. 112 funds tracked by Wall St. Rank hold KYNB as of Q1 2024.

  • Natixis reported no remaining Kyntra Bio position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 1,200 Kyntra Bio shares in Q1 2024, an estimated $26.6K.
  • Natixis first reported a position in Kyntra Bio in Q3 2018 and held it in 10 quarters.
  • Natixis's Kyntra Bio position peaked at $9.14M in Q3 2020.
  • 112 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.